ApoE and Other Diseases

Type 2 diabetes, APOE gene, and the risk for dementia and related pathologies: The Honolulu-Asia Aging Study. Peila, R., Rodriguez, B. L., Launer, L. J., & Honolulu-Asia Aging Study (2002).  Diabetes51(4), 12561262.

The association between apolipoprotein E gene polymorphisms and essential hypertension: a meta-analysis of 45 studies including 13,940 cases and 16,364 controls. Stoumpos, S., Hamodrakas, S. J., Anthopoulos, P. G., & Bagos, P. G. (2013).  Journal of human hypertension27(4), 245255.

Association between ApoE polymorphism and hypertension: A meta-analysis of 28 studies including 5898 cases and 7518 controls. Shia, J. , Liua, Y., Liu, Y., Lia, Y., Qiua, S., Baia, Y., Gua, Y., Luoa, J., Cuia, H., Lia, Y., Zhaoa, Q., Zhang, K., Cheng K.,  Gene, Volume 675, 30 October 2018, Pages 197-207.

Association of ApoE Genetic Polymorphism and Type 2 Diabetes with Cognition in Non-Demented Aging Chinese Adults: A Community Based Cross-Sectional Study. Zhen, J., Lin, T., Huang, X., Zhang, H., Dong, S., Wu, Y., Song, L., Xiao, R., & Yuan, L. (2018).  Aging and disease9(3), 346357.

Apolipoprotein E levels and apolipoprotein E genotypes in incident cardiovascular disease risk in subjects of the Prevention of Renal and Vascular End-stage disease study. Corsetti, J. P., Gansevoort, R. T., Bakker, S., & Dullaart, R. (2016).  Journal of clinical lipidology10(4), 842850.

Apolipoprotein E controls cerebrovascular integrity via cyclophilin A. Bell, R. D., Winkler, E. A., Singh, I., Sagare, A. P., Deane, R., Wu, Z., Holtzman, D. M., Betsholtz, C., Armulik, A., Sallstrom, J., Berk, B. C., & Zlokovic, B. V. (2012).  Nature485(7399), 512516.

Accelerated pericyte degeneration and blood-brain barrier breakdown in apolipoprotein E4 carriers with Alzheimer’s disease. Halliday, M. R., Rege, S. V., Ma, Q., Zhao, Z., Miller, C. A., Winkler, E. A., & Zlokovic, B. V. (2016).  Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism36(1), 216227.

Apolipoprotein E4 impairs spontaneous blood brain barrier repair following traumatic brain injury. Main BS, Villapol S, Sloley SS, Barton DJ, Parsadanian M, Agbaegbu C, Stefos K, McCann MS, Washington PM, Rodriguez OC, Burns MP. Mol Neurodegener. 2018 Apr 4;13(1):17.

Cerebrovascular amyloid Angiopathy in bioengineered vessels is reduced by high-density lipoprotein particles enriched in Apolipoprotein E. Robert J, Button EB, Martin EM, McAlary L, Gidden Z, Gilmour M, Boyce G, Caffrey TM, Agbay A, Clark A, Silverman JM, Cashman NR, Wellington CL.  Mol Neurodegener. 2020 Mar 25;15(1):23.

Blood-brain barrier-associated pericytes internalize and clear aggregated amyloid-β42 by LRP1-dependent apolipoprotein E isoform-specific mechanism. Ma Q, Zhao Z, Sagare AP, Wu Y, Wang M, Owens NC, Verghese PB, Herz J, Holtzman DM, Zlokovic BV.  Mol Neurodegener. 2018 Oct 19;13(1):57.

Glymphatic distribution of CSF-derived apoE into brain is isoform specific and suppressed during sleep deprivation. Achariyar TM, Li B, Peng W, Verghese PB, Shi Y, McConnell E, Benraiss A, Kasper T, Song W, Takano T, Holtzman DM, Nedergaard M, Deane R.  Mol Neurodegener. 2016 Dec 8;11(1):74.

A rapid and cost-effective method for genotyping apolipoprotein E gene polymorphism. Zhong L, Xie YZ, Cao TT, Wang Z, Wang T, Li X, Shen RC, Xu H, Bu G, Chen XF.  Mol Neurodegener. 2016 Jan 12;11:2